Comparación de ixekizumab y adalimumab en el tratamiento de la psoriasis ungueal en pacientes con artritis psoriásica con psoriasis moderada a grave: resultados a las 24 semanas de un estudio multicéntrico, aleatorizado, abierto, evaluador ciego (SPIRIT-H2H)
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Mensajes clave
- La psoriasis ungueal es común en pacientes con artritis psoriásica y psoriasis, y compromete del 80% al 90% de las personas con psoriasis en algún momento de su vida.
- Este análisis post-hoc, de subgrupos, del estudio SPIRIT-H2H (NCT03151551) comparó la eficacia del antagonista de IL-17A, ixekizumab, y el bloqueante de TNF-alfa, adalimumab, para resolver la psoriasis ungueal a la semana 24 en pacientes con artritis psoriásica activa y psoriasis de moderada a grave.
- En este análisis post-hoc, ixekizumab (80,0%) mostró tasas significativamente más altas de resolución completa del compromiso ungueal que adalimumab (52,5%) a la semana 24, confirmando la eficacia establecida de ixekizumab en la psoriasis ungueal.
- Esto confirma la eficacia establecida de ixekizumab en la psoriasis ungueal.
Presenting Author
Saxon D. Smith, MBChB, MHL, PhD
Northern Clinical School, Sydney Medical School, The University of Sydney
Sydney, Australia
Dr Saxon D Smith is a Fellow of the Australasian College of Dermatologists. He graduated medicine from the University of Otago, Dunedin, New Zealand, and has a Master Degree in Health Law from the University of Sydney. He completed his Doctor of Philosophy (Medicine) at the University of Sydney.
Dr Smith is the principal dermatologist at The Dermatology and Skin Cancer Centre in Gosford and St Leonards, NSW, Australia. He has been a clinical supervisor for dermatology trainees, higher degree by research students, and University of Sydney Doctorate of Medicine (MD) research supervisor/tutor. He has performed research in a broad range of areas in medical and surgical dermatology including adult and paediatric atopic dermatitis, adult and paediatric psoriasis, hidradentitis suppurativa, as well as the surgical and non-surgical management of non-melanoma skin cancer and melanoma. He is also currently involved in multiple pharmaceutical trials from phase II to phase IV.
Dr Smith has been a key note speaker and invited speaker to national and international conferences. He has over 75 peer reviewed journal publications and over 100 published abstracts.
Author disclosures
Saxon D. Smith: Advisory Panel: Abbvie, Biogen, Eli Lilly and Company, Janssen-Cilag, Johnson and Johnson Consumer Products Company, Novartis, Pfizer, Sanofi Genzyme; Research Support: Abbvie, BMS, Eli Lilly and Company, Novartis, Sanofi Genzyme, UCB, Regeneron; Speaker’s Bureau: Abbvie, Eli Lilly and Company, Leo, Novartis; Honoraria: Energizer Holdings, Inc.
